+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Mitochondrial Dysfunctions in Type I Endometrial Carcinoma: Exploring Their Role in Oncogenesis and Tumor Progression



Mitochondrial Dysfunctions in Type I Endometrial Carcinoma: Exploring Their Role in Oncogenesis and Tumor Progression



International Journal of Molecular Sciences 19(7)



Type I endometrial cancer (EC) is the most common form of EC, displaying less aggressive behavior than type II. The development of type I endometrial cancer is considered a multistep process, with slow progression from normal endometrium to hyperplasia, the premalignant form, and endometrial cancer as a result of an unopposed estrogenic stimulation. The role of mitochondria in type I EC tumor progression and prognosis is currently emerging. This review aims to explore mitochondrial alterations in this cancer and in endometrial hyperplasia focusing on mitochondrial DNA mutations, respiratory complex I deficiency, and the activation of mitochondrial quality control systems. A deeper understanding of altered mitochondrial pathways in type I EC could provide novel opportunities to discover new diagnostic and prognostic markers as well as potential therapeutic targets.

(PDF emailed within 0-6 h: $19.90)

Accession: 065322901

Download citation: RISBibTeXText

PMID: 30018222

DOI: 10.3390/ijms19072076


Related references

Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Human Molecular Genetics 20(12): 2394-2405, 2011

The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma. Gynecologic Oncology 148(2): 383-392, 2017

Mitochondrial changes in endometrial carcinoma: possible role in tumor diagnosis and prognosis (review). Oncology Reports 33(3): 1011-1018, 2015

Mitochondrial dysfunctions in bladder cancer: Exploring their role as disease markers and potential therapeutic targets. Critical Reviews in Oncology/Hematology 117: 67-72, 2017

Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Research 60(24): 7052-7056, 2001

Amplification studies of MET and Cdk6 in a rat endometrial tumor model and their correlation to human type I endometrial carcinoma tumors. Advances in Experimental Medicine and Biology 617: 511-517, 2008

The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression. Molecular and Cellular Oncology 2(1): E970955, 2015

HIF-1α and GLUT-1 Expression in Atypical Endometrial Hyperplasia, Type I and II Endometrial Carcinoma: A Potential Role in Pathogenesis. Journal of Clinical and Diagnostic Research 10(5): Ec20-Ec27, 2016

Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis. Tumour Biology 36(6): 4479-4485, 2015

Role of tumor-associated glycoprotein-72 in the progression of endometrial adenocarcinoma: a proposed study. Medical Hypotheses 84(5): 413-416, 2015

Tumor Budding is a Valuable Diagnostic Parameter in Prediction of Disease Progression of Endometrial Endometrioid Carcinoma. Pathology Oncology Research 2019, 2019

TESTIN suppresses tumor growth and invasion via manipulating cell cycle progression in endometrial carcinoma. Medical Science Monitor 20: 980-987, 2014

Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update. Endocrine-Related Cancer 23(2): R85-R111, 2016

Complex I deficiency associated to mitochondrial DNA mutations in type I endometrial carcinoma. Biochimica et Biophysica Acta - Bioenergetics 1817: S53-S54, 2012

Mitochondrial dysfunctions during progression of dystrophic cardiomyopathy. Cell Calcium 58(2): 186-195, 2016